Research Alliance Corp. Iv IPO: What Investors Need to Know
Research Alliance Corp. Iv (NASDAQ: RACD) is expected to list on 2026-07-13. The company has not disclosed a price range yet, and the IPO is for 7,500,000 shares. This is a healthcare-focused SPAC, so the key question is whether the sponsor can find a strong target before the 24-month deadline.
Research Alliance Corp. Iv (NASDAQ: RACD) is expected to list on 2026-07-13. The company has not disclosed a price range yet, and the IPO is for 7,500,000 shares. This is a healthcare-focused SPAC, so the key question is whether the sponsor can find a strong target before the 24-month deadline.
Research Alliance Corp. Iv is a Cayman Islands exempted blank-check company formed to complete a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. It has not selected a target and has not initiated substantive discussions with any target. The filing says it intends to focus on healthcare or healthcare-related industries, which fits the background of its leadership and sponsor group.
The company was incorporated on April 1, 2026, and its principal executive offices are in New York. As a SPAC, it does not operate a product business today; instead, it raises cash in an IPO and holds most of the proceeds in trust while searching for a private company to take public. The broader healthcare deal market is the real backdrop here: the filing cites $300 billion in annual revenue at risk from loss of exclusivity in 2026-2031 and 216 M&A transactions totaling $534.0 billion since 2020, which helps explain why healthcare remains a popular hunting ground for acquisition vehicles.
Why They're Going Public
The IPO is designed to fund the trust account and give the company capital to pursue its future business combination. The public offering is expected to raise $75.0 million, and the sponsor has also committed to buy 275,000 private placement shares for $2.75 million. The filing says funds outside the trust may be used for working capital and expenses tied to the initial business combination.
Going public also gives the sponsor a currency and a structure to move quickly once a target is identified. For a SPAC, the listing is less about scaling an existing business and more about creating a capital pool and a public-market path for a future transaction. The setup only works if management can source a credible healthcare deal and complete it within 24 months of the offering closing.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
There is no operating revenue to analyze because Research Alliance Corp. Iv is a blank-check company. The filing explicitly says it has generated no operating revenues to date and will not generate operating revenues until after a business combination. That means there is no gross margin, customer count, or operating growth trend yet.
The disclosed financials are minimal and reflect an early-stage shell. The company reported a net loss of $14,526 for the period from April 1, 2026 through April 7, 2026, cash at end of period of $0, and total shareholder’s equity of $10,474 at April 7, 2026. For investors, the more relevant number is the IPO structure itself: 7,500,000 Class A ordinary shares at $10.00 per share for gross proceeds of $75.0 million, plus the sponsor’s $2.75 million private placement commitment.
Risk Factors
The biggest risk is straightforward: this is a SPAC with no target. There is no operating business, no revenue base, and no assurance that management will complete a business combination at all. If the company does not close a deal within 24 months, it faces liquidation risk, and shareholders should watch the redemption mechanics closely because a large redemption can shrink the cash available for a transaction.
There are also structural risks that matter more than they do for a normal operating company. The filing highlights conflicts of interest because officers and directors are also involved with Research Alliance Corp III and other RA Capital vehicles, which could limit access to the same targets. Dilution is another issue: founder shares, private placement shares, and the possibility of issuing additional shares or debt in a business combination can reduce the economic value of the public float. The private placement shares are not transferable until 30 days after the initial business combination, and founder shares can unlock if the Class A shares trade at or above $12.00 for 20 trading days within any 30-trading-day period beginning at least 150 days after the deal closes.
Comparable Public Companies
Because Research Alliance Corp. Iv is a SPAC, the closest public comparables are other blank-check vehicles rather than operating healthcare companies. The most relevant reference point from the filing is Research Alliance Corp III, which sits in the same sponsor ecosystem and underscores the competitive pressure for targets. Outside that, healthcare-focused SPACs are the best comp set conceptually, but the filing does not provide a formal peer table or valuation multiples.
For a broader market read, investors often compare SPACs against the public-market appetite for healthcare dealmaking rather than against revenue multiples. That backdrop is mixed: healthcare M&A remains active, but blank-check structures have to compete for attention against a market that tends to reward clear operating growth more than future optionality. Since this is a pre-pricing IPO with no disclosed range, there is no trading history to anchor valuation, and the main question is whether the sponsor’s healthcare focus and RA Capital brand are enough to attract capital in a still-selective SPAC market.
Verdict
The setup is best viewed as a what-to-watch story rather than a valuation call. Research Alliance Corp. Iv is a standard healthcare-focused SPAC with a $75.0 million public offering, no disclosed price range yet, and no target identified, so the key items to watch as it prices are the final terms, investor demand, and how much cash actually lands in trust after any redemptions. The structure is notable because the filing says it does not include warrants, which makes it stand out from many SPAC offerings.
The market-timing angle is the real hook here: healthcare M&A is still active, and the filing leans on a sector narrative built around patent cliffs, licensing, and strategic acquisitions. That gives RACD a relevant story at a time when investors are still selective on SPACs, but the deal will ultimately live or die on target quality and execution. Shareholders should watch whether the sponsor can turn the RA Capital healthcare platform into a credible acquisition before the 24-month clock runs out.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
